/**
 * Quiz Data for GSAPS Courses
 * Comprehensive quiz questions for course assessments
 */

export const QUIZ_DATA = {
  // Course 1: Introduction to Psychedelic-Assisted Therapy
  'intro-psychedelic-therapy': {
    'module-1-quiz': {
      title: 'Module 1 Assessment: Foundations and History',
      passingScore: 70,
      questions: [
        {
          question: 'Which indigenous culture is traditionally associated with ayahuasca ceremonies?',
          options: [
            'Amazonian tribes of South America',
            'Native American Plains tribes',
            'Aboriginal Australians',
            'Polynesian islanders'
          ],
          correctAnswer: 'Amazonian tribes of South America',
          explanation: 'Ayahuasca has been used for centuries by indigenous peoples of the Amazon basin for spiritual and healing purposes.'
        },
        {
          question: 'Who synthesized LSD in 1938?',
          options: [
            'Timothy Leary',
            'Albert Hofmann',
            'Alexander Shulgin',
            'Humphry Osmond'
          ],
          correctAnswer: 'Albert Hofmann',
          explanation: 'Albert Hofmann, a Swiss chemist working for Sandoz, first synthesized LSD-25 in 1938 and discovered its psychoactive effects in 1943.'
        },
        {
          question: 'What Schedule classification does the DEA assign to most psychedelics?',
          options: [
            'Schedule I',
            'Schedule II',
            'Schedule III',
            'Schedule IV'
          ],
          correctAnswer: 'Schedule I',
          explanation: 'Most classic psychedelics are classified as Schedule I, indicating "no currently accepted medical use" and high potential for abuse, though this is being challenged by modern research.'
        },
        {
          question: 'Which organization has been instrumental in funding modern psychedelic research?',
          options: [
            'National Institute of Health (NIH)',
            'Centers for Disease Control (CDC)',
            'Multidisciplinary Association for Psychedelic Studies (MAPS)',
            'Food and Drug Administration (FDA)'
          ],
          correctAnswer: 'Multidisciplinary Association for Psychedelic Studies (MAPS)',
          explanation: 'MAPS has been the primary non-profit funding and conducting psychedelic research, particularly MDMA for PTSD, since its founding in 1986.'
        },
        {
          question: 'When did the "Psychedelic Renaissance" generally begin?',
          options: [
            'Late 1980s',
            'Early 1990s',
            'Late 1990s/Early 2000s',
            'Mid 2010s'
          ],
          correctAnswer: 'Late 1990s/Early 2000s',
          explanation: 'The resurgence of psychedelic research began in the late 1990s and early 2000s with renewed academic interest and regulatory approval for human studies.'
        }
      ]
    },
    'module-2-quiz': {
      title: 'Module 2 Assessment: Pharmacology and Neuroscience',
      passingScore: 70,
      questions: [
        {
          question: 'Which neurotransmitter system is primarily affected by classic psychedelics like psilocybin and LSD?',
          options: [
            'Dopamine',
            'GABA',
            'Serotonin (5-HT)',
            'Acetylcholine'
          ],
          correctAnswer: 'Serotonin (5-HT)',
          explanation: 'Classic psychedelics primarily act as agonists at the serotonin 5-HT2A receptor, which is responsible for their psychoactive effects.'
        },
        {
          question: 'What is the primary mechanism by which psychedelics may promote neuroplasticity?',
          options: [
            'Increasing BDNF (Brain-Derived Neurotrophic Factor)',
            'Blocking NMDA receptors',
            'Enhancing GABA transmission',
            'Inhibiting monoamine oxidase'
          ],
          correctAnswer: 'Increasing BDNF (Brain-Derived Neurotrophic Factor)',
          explanation: 'Psychedelics promote neuroplasticity by increasing BDNF, promoting dendritic growth, and enhancing synaptic connectivity.'
        },
        {
          question: 'What brain region shows decreased activity during psychedelic experiences?',
          options: [
            'Amygdala',
            'Hippocampus',
            'Default Mode Network (DMN)',
            'Visual cortex'
          ],
          correctAnswer: 'Default Mode Network (DMN)',
          explanation: 'The Default Mode Network, associated with self-referential thinking and the ego, shows decreased activity during psychedelic experiences, correlating with ego dissolution.'
        },
        {
          question: 'What is "set and setting" in psychedelic therapy?',
          options: [
            'The dosage and timing of administration',
            'The mindset of the participant and the physical/social environment',
            'The type of psychedelic and route of administration',
            'The therapeutic protocol and outcome measures'
          ],
          correctAnswer: 'The mindset of the participant and the physical/social environment',
          explanation: '"Set and setting" refers to the psychological mindset (set) and physical/social environment (setting), both crucial determinants of the psychedelic experience.'
        },
        {
          question: 'Approximately how long does a psilocybin experience typically last?',
          options: [
            '2-3 hours',
            '4-6 hours',
            '8-12 hours',
            '24+ hours'
          ],
          correctAnswer: '4-6 hours',
          explanation: 'A psilocybin experience typically lasts 4-6 hours, with effects beginning 20-40 minutes after ingestion and peaking at 2-3 hours.'
        }
      ]
    },
    'module-3-quiz': {
      title: 'Module 3 Assessment: Clinical Applications',
      passingScore: 70,
      questions: [
        {
          question: 'Which condition has shown the most robust clinical evidence for psilocybin treatment?',
          options: [
            'Schizophrenia',
            'Treatment-resistant depression',
            'ADHD',
            'Bipolar disorder'
          ],
          correctAnswer: 'Treatment-resistant depression',
          explanation: 'Psilocybin has demonstrated significant efficacy in treating treatment-resistant depression in multiple clinical trials, with effects lasting months after treatment.'
        },
        {
          question: 'What is a major contraindication for psychedelic therapy?',
          options: [
            'History of anxiety',
            'Mild depression',
            'Personal or family history of psychosis',
            'Previous use of antidepressants'
          ],
          correctAnswer: 'Personal or family history of psychosis',
          explanation: 'Psychosis or family history of psychotic disorders is a major contraindication due to risk of triggering or exacerbating psychotic symptoms.'
        },
        {
          question: 'In clinical trials, how many psilocybin dosing sessions are typically administered?',
          options: [
            'Daily for one week',
            '1-3 sessions spaced weeks apart',
            '6-8 sessions over 3 months',
            'Weekly for 6 months'
          ],
          correctAnswer: '1-3 sessions spaced weeks apart',
          explanation: 'Most clinical protocols involve 1-3 high-dose psilocybin sessions, typically spaced 2-4 weeks apart, with preparation and integration sessions in between.'
        },
        {
          question: 'What role do therapists typically play during a psilocybin dosing session?',
          options: [
            'Actively directing and interpreting the experience',
            'Providing non-directive support and ensuring safety',
            'Administering cognitive behavioral interventions',
            'Conducting psychoanalysis during the peak'
          ],
          correctAnswer: 'Providing non-directive support and ensuring safety',
          explanation: 'Therapists adopt a non-directive, supportive role, allowing the participant to have their own experience while ensuring physical and psychological safety.'
        },
        {
          question: 'What percentage of participants in cancer-related anxiety studies reported sustained benefits 6-12 months post-treatment?',
          options: [
            '20-30%',
            '40-50%',
            '60-70%',
            '80-90%'
          ],
          correctAnswer: '60-70%',
          explanation: 'Approximately 60-80% of participants in psilocybin studies for cancer-related anxiety reported sustained clinically significant reductions in anxiety and depression 6-12 months after treatment.'
        }
      ]
    },
    'final-exam': {
      title: 'Final Comprehensive Exam',
      passingScore: 70,
      questions: [
        {
          question: 'What is the primary difference between "classical" and "non-classical" psychedelics?',
          options: [
            'Classical are plant-based, non-classical are synthetic',
            'Classical act on serotonin 5-HT2A receptors, non-classical work through other mechanisms',
            'Classical are legal, non-classical are Schedule I',
            'Classical cause ego dissolution, non-classical do not'
          ],
          correctAnswer: 'Classical act on serotonin 5-HT2A receptors, non-classical work through other mechanisms',
          explanation: 'Classical psychedelics (psilocybin, LSD, mescaline) primarily act as 5-HT2A agonists, while non-classical psychedelics like ketamine and MDMA work through different mechanisms.'
        },
        {
          question: 'Which preparation activity is MOST important before a psychedelic dosing session?',
          options: [
            'Fasting for 24 hours',
            'Meditation practice',
            'Building therapeutic rapport and trust',
            'Learning about neuroscience'
          ],
          correctAnswer: 'Building therapeutic rapport and trust',
          explanation: 'Establishing strong therapeutic rapport and trust is crucial for creating psychological safety, which significantly impacts the quality and therapeutic value of the experience.'
        },
        {
          question: 'What is "integration" in psychedelic-assisted therapy?',
          options: [
            'Combining psychedelics with other medications',
            'Incorporating insights from the experience into daily life and therapy',
            'Integrating different therapeutic modalities',
            'Merging preparation and dosing sessions'
          ],
          correctAnswer: 'Incorporating insights from the experience into daily life and therapy',
          explanation: 'Integration involves processing the psychedelic experience and incorporating insights, emotional shifts, and new perspectives into ongoing life and therapeutic work.'
        },
        {
          question: 'According to current research, what appears to mediate the therapeutic effects of psychedelics?',
          options: [
            'Duration of the experience',
            'Dosage amount only',
            'Quality of the mystical/peak experience',
            'Number of sessions'
          ],
          correctAnswer: 'Quality of the mystical/peak experience',
          explanation: 'Research suggests that the quality and depth of mystical-type experiences, including feelings of unity, transcendence, and awe, correlates with therapeutic outcomes.'
        },
        {
          question: 'What ethical principle is MOST important when working with psychedelic medicine?',
          options: [
            'Maximizing profit',
            'Ensuring informed consent and participant autonomy',
            'Promoting specific spiritual beliefs',
            'Achieving the highest possible doses'
          ],
          correctAnswer: 'Ensuring informed consent and participant autonomy',
          explanation: 'Informed consent, respect for autonomy, and beneficence are paramount ethical principles, especially given the vulnerable psychological states induced by psychedelics.'
        },
        {
          question: 'What is currently the legal status of psilocybin therapy in the United States (as of 2024)?',
          options: [
            'Fully legal nationwide',
            'Available through FDA Expanded Access for specific conditions',
            'Decriminalized in all states',
            'Only legal in clinical trials or state-approved programs'
          ],
          correctAnswer: 'Only legal in clinical trials or state-approved programs',
          explanation: 'Psilocybin remains federally Schedule I but is available through FDA-approved clinical trials and in certain state programs (Oregon, Colorado) for therapeutic use.'
        },
        {
          question: 'What is a "challenging" or "difficult" psychedelic experience sometimes called?',
          options: [
            'Bad trip',
            'Psychotic break',
            'Adverse reaction',
            'All of the above terms may be used'
          ],
          correctAnswer: 'All of the above terms may be used',
          explanation: 'Various terms are used, though clinicians prefer "challenging experience" as it acknowledges difficulty without pathologizing potentially therapeutic experiences.'
        },
        {
          question: 'Which condition is MDMA-assisted therapy primarily being studied for?',
          options: [
            'Depression',
            'PTSD (Post-Traumatic Stress Disorder)',
            'Anxiety',
            'Addiction'
          ],
          correctAnswer: 'PTSD (Post-Traumatic Stress Disorder)',
          explanation: 'MDMA-assisted therapy for PTSD has completed Phase 3 trials with promising results and is seeking FDA approval for clinical use.'
        },
        {
          question: 'What role does music typically play in psychedelic therapy sessions?',
          options: [
            'It is avoided to prevent distraction',
            'It provides emotional support and guidance during the experience',
            'It is only used during preparation sessions',
            'It must be classical music only'
          ],
          correctAnswer: 'It provides emotional support and guidance during the experience',
          explanation: 'Carefully curated music is integral to psychedelic therapy, providing emotional support, facilitating emotional release, and guiding the arc of the experience.'
        },
        {
          question: 'What is the approximate remission rate for treatment-resistant depression with psilocybin in recent trials?',
          options: [
            '10-20%',
            '30-40%',
            '50-60%',
            '70-80%'
          ],
          correctAnswer: '50-60%',
          explanation: 'Recent studies show remission rates of approximately 50-60% for treatment-resistant depression following psilocybin-assisted therapy, significantly higher than conventional treatments.'
        }
      ]
    }
  },

  // Course 2: MDMA-Assisted Therapy for PTSD
  'mdma-ptsd-training': {
    'module-1-quiz': {
      title: 'Module 1 Assessment: MDMA Foundations',
      passingScore: 70,
      questions: [
        {
          question: 'What is MDMA\'s primary mechanism of action?',
          options: [
            'Selective serotonin reuptake inhibition',
            'Release of serotonin, norepinephrine, and dopamine',
            'NMDA receptor antagonism',
            'Mu-opioid receptor agonism'
          ],
          correctAnswer: 'Release of serotonin, norepinephrine, and dopamine',
          explanation: 'MDMA causes the release of monoamines (serotonin, norepinephrine, dopamine) and also releases oxytocin, contributing to its unique empathogenic effects.'
        },
        {
          question: 'What is the typical duration of an MDMA therapy session?',
          options: [
            '2-3 hours',
            '4-6 hours',
            '6-8 hours',
            '10-12 hours'
          ],
          correctAnswer: '6-8 hours',
          explanation: 'MDMA therapy sessions typically last 6-8 hours, allowing time for onset, peak effects, and gradual return to baseline with therapist support throughout.'
        },
        {
          question: 'In MAPS PTSD trials, how many MDMA dosing sessions are typically administered?',
          options: [
            '1 session',
            '2 sessions',
            '3 sessions',
            '5 sessions'
          ],
          correctAnswer: '3 sessions',
          explanation: 'The MAPS protocol typically involves 3 MDMA-assisted therapy sessions, each spaced 3-5 weeks apart, with preparatory and integration sessions between dosing sessions.'
        },
        {
          question: 'What is the approximate success rate for MDMA-assisted therapy in Phase 3 PTSD trials?',
          options: [
            '30-40%',
            '50-60%',
            '67-71%',
            '85-90%'
          ],
          correctAnswer: '67-71%',
          explanation: 'MAPS Phase 3 trials showed that 67-71% of participants no longer met PTSD diagnostic criteria after MDMA-assisted therapy, compared to 32% in the placebo group.'
        },
        {
          question: 'What makes MDMA particularly effective for PTSD treatment?',
          options: [
            'It erases traumatic memories',
            'It reduces fear response while maintaining cognitive function for trauma processing',
            'It acts as a sedative to calm anxiety',
            'It creates amnesia for traumatic events'
          ],
          correctAnswer: 'It reduces fear response while maintaining cognitive function for trauma processing',
          explanation: 'MDMA decreases amygdala activity (fear response) while maintaining prefrontal cortex function, creating an optimal state for processing traumatic memories without overwhelming fear.'
        }
      ]
    }
  }
};

export default QUIZ_DATA;
